UCB, Daiichi Sankyo deal

UCB granted Daiichi Sankyo co-commercialization rights in Japan to epilepsy drug Vimpat lacosamide. Next year, UCB plans to submit regulatory applications in Japan and China for Vimpat as adjunctive ...